New immune therapies aim to tackle High-Risk myeloma early
NCT ID NCT05849610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 pilot study tests two new drug combinations—teclistamab plus daratumumab and talquetamab plus daratumumab—in 30 people newly diagnosed with high-risk multiple myeloma. The goal is to see if these treatments can make the cancer undetectable (MRD-negative complete remission) after initial therapy. Participants first receive standard induction therapy, then one of the two experimental combinations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teclistamab and talquetamab (bispecific T-cell redirectors) plus daratumumab, bortezomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this could offer a more effective early treatment for high-risk multiple myeloma, potentially leading to deeper remissions and longer disease control.
What could go wrong
This is a small, early-phase pilot study with only 30 participants, so results may not apply broadly. Bispecific antibodies can cause serious side effects like cytokine release syndrome and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK DE NOVO MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Complejo Hospitalario Santiago (CHUS)
Santiago de Compostela, Spain
-
H. Universitario Marqués de Valdecilla
Santander, Spain
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain
-
Hospital Doce de Octubre
Madrid, 28041, Spain
-
Hospital Germans Trials i Pujol
Badalona, Spain
-
Hospital Universitari i Politecnic la Fe
Valencia, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
Hospital Virgen de la Arrixaca
Murcia, Spain
-
Hospital Vírgen del Rocío
Seville, Spain